154 related articles for article (PubMed ID: 16906374)
1. CD19/22 balance relates to improvement of disease activity in systemic lupus erythematosus.
Suzuki J; Nakano S; Nakairi Y; Mitsuo A; Amano H; Morimoto S; Tokano Y; Takasaki Y
Mod Rheumatol; 2006; 16(4):235-8. PubMed ID: 16906374
[TBL] [Abstract][Full Text] [Related]
2. Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus.
El-Sayed ZA; Ragab SM; Khalifa KA; El Ashmawy RA
Egypt J Immunol; 2009; 16(1):27-38. PubMed ID: 20726320
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
4. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population.
Wu O; Chen GP; Chen H; Li XP; Xu JH; Zhao SS; Sheng J; Feng JB; Cai J; Fang XH; Zhang WH; Li LH; Zhang N; Li J; Li JJ; Pan FM; Wang CZ; Ye DQ
Immunobiology; 2009; 214(5):392-402. PubMed ID: 19362685
[TBL] [Abstract][Full Text] [Related]
5. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.
Iwata S; Yamaoka K; Niiro H; Jabbarzadeh-Tabrizi S; Wang SP; Kondo M; Yoshikawa M; Akashi K; Tanaka Y
Lupus; 2015 Jun; 24(7):695-704. PubMed ID: 25432781
[TBL] [Abstract][Full Text] [Related]
6. Elevated CD19
Ju B; Wang J; Mo L; Huang J; Hao Z; Lv X; Pu D; He L
Int Immunopharmacol; 2022 Jan; 102():108403. PubMed ID: 34857478
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
8. The potential role of Ets-1 and miR-326 in CD19
Jin L; Fang X; Dai C; Xiang N; Tao J; Sun X; Azmi F; Cao Q; Li X; Wang Y; Li X
Clin Rheumatol; 2019 Apr; 38(4):1031-1038. PubMed ID: 30456527
[TBL] [Abstract][Full Text] [Related]
9. CD81 and CD19 as Marker of Activity in Systemic Lupus Erythematosus Disease.
Abu-Zahab Z; Gad NM; Sabry S; Nassib SA
Egypt J Immunol; 2017 Jun; 24(2):141-149. PubMed ID: 29528587
[TBL] [Abstract][Full Text] [Related]
10. Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naïve systemic lupus erythematosus.
Jin L; Weiqian C; Lihuan Y
Int J Rheum Dis; 2013 Dec; 16(6):698-708. PubMed ID: 24286662
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of percentage of lymphocytes B with expression of co-receptors CD 40, CD22 and CD72 in hypertrophied adenoid at children with otitis media with effusion].
Wysocka J; Zelazowska-Rutkowska B; Ratomski K; Skotnicka B; Hassmann-Poznańska E
Otolaryngol Pol; 2009; 63(6):504-8. PubMed ID: 20198985
[TBL] [Abstract][Full Text] [Related]
12. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
[TBL] [Abstract][Full Text] [Related]
13. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity.
Bijl M; Horst G; Limburg PC; Kallenberg CG
Lupus; 2001; 10(12):866-72. PubMed ID: 11787876
[TBL] [Abstract][Full Text] [Related]
14. [The abnormality of FcgammaRIIB1-mediated signaling and the hyperactivity of B cells from patients with systemic lupus erythematosus].
Peng KJ; Xiao LS; Fei Y; Wang SR
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Nov; 22(6):769-71. PubMed ID: 17077019
[TBL] [Abstract][Full Text] [Related]
15. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
[TBL] [Abstract][Full Text] [Related]
16. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
[TBL] [Abstract][Full Text] [Related]
17. Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus.
Taher TE; Parikh K; Flores-Borja F; Mletzko S; Isenberg DA; Peppelenbosch MP; Mageed RA
Arthritis Rheum; 2010 Aug; 62(8):2412-23. PubMed ID: 20506108
[TBL] [Abstract][Full Text] [Related]
18. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.
Melissaropoulos K; Liossis SN
Rheumatol Int; 2018 Jul; 38(7):1225-1234. PubMed ID: 29869007
[TBL] [Abstract][Full Text] [Related]
19. [Role of transcription factor ETS-1 and B cell in the pathogenesis of systemic lupus erythematosus].
Ren QJ; Li XP; Tao JH; Yu N; Li XM; Wang GS; Zhang H; Fang X
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2483-6. PubMed ID: 24300270
[TBL] [Abstract][Full Text] [Related]
20. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
